Megan Blewett is an investor at Scion Life Sciences.
Blewett co-founded and led Iris Medicine, whose mission is to develop genetically targeted treatments for neurodegenerative disorders. Prior to Iris, she co-founded Kelonia Therapeutics, a company advancing tissue-specific gene delivery. Blewett was previously a venture capital investor at Venrock with an emphasis on therapeutics and biotech company creation.
Blewett earned a PhD in chemistry as a Hertz fellow with Benjamin Cravatt at The Scripps Research Institute. Her PhD work helped form the foundation of Vividion, which was acquired by Bayer in 2021. Blewett received her AB/AM from Harvard, where she conducted research in the lab of Novel laureate EJ Corey. She has been named to the Forbes 30 under 30 list for Healthcare and Business Insider’s Under 40 in Biotech.
In addition to her work in biotech, Blewett serves on the Board of two non-profits, Convergent Research and Pioneer Labs, that are dedicated to advancing early-stage research in areas of high unmet need.
